DLA Piper advises Histogen in its US$14 million upsized public offering

Rhea-AI Summary

Histogen, Inc. (NASDAQ: HSTO) announced a public offering of 11,600,000 shares of common stock, pre-funded warrants for 2,400,000 shares, and warrants for 14,000,000 shares, priced at $1.00 each. This upsized offering aims to raise $14 million to enhance its research and development efforts for innovative therapies that support biological function. DLA Piper represented Histogen in this transaction, highlighting their expertise in the life sciences sector.

Positive

• The public offering aims to raise $14 million to expand research and development efforts.
• The funds will support the advancement of innovative therapeutic solutions.

Negative

• Dilution of existing shareholders due to the issuance of new shares.

NEW YORK, Jan. 7, 2021 /PRNewswire/ -- DLA Piper represented advised Histogen, Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body's natural process to repair and maintain healthy biological function, in its public offering of 11,600,000 shares of common stock, pre-funded warrants to purchase up to 2,400,000 shares of common stock and warrants to purchase up to an aggregate of 14,000,000 shares of common stock at a price of $1.00 per share.

"We were pleased to bring our extensive experience helping life sciences companies access the capital markets to close this transaction. This funding will allow Histogen to expand its research and development efforts as it continues to advance innovative therapeutic solutions," said Larry Nishnick, the DLA Piper partner who led the firm's deal team.

In addition to Nishnick (San Diego), the DLA Piper team advising Histogen included partner Patrick O'Malley (San Diego) and associate Kathryn Fortin (San Diego).

DLA Piper's global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.

DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients' needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company. 

About DLA Piper
DLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com

 

View original content:http://www.prnewswire.com/news-releases/dla-piper-advises-histogen-in-its-us14-million-upsized-public-offering-301202841.html

SOURCE DLA Piper

FAQ

What is the purpose of Histogen's recent public offering?

The public offering aims to raise $14 million to enhance research and development efforts for new therapeutic solutions.

How many shares is Histogen offering in its public offering?

Histogen is offering 11,600,000 shares of common stock, along with pre-funded warrants and additional warrants.

What will the proceeds from Histogen's offering be used for?

The proceeds will be used to expand Histogen's research and development initiatives.

What is the price per share in Histogen's public offering?

The shares are priced at $1.00 each.

What impact might the public offering have on existing shareholders of HSTO?

The public offering may lead to dilution of existing shares, affecting current shareholders' equity.